# GIMEMA LAL2317 (NCT03367299)

> Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

- Drugs tested: blinatumomab plus chemotherapy
- Indication: adult Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03367299
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- Conditions: Acute Lymphoid Leukemia; Philadelphia Chromosome-Negative B-Cell Precursor
- Interventions: Chemotherapy + Blinatumomab
- Enrollment: 149
- Primary outcome: Number of patients that obtain a negative Minimal Residual Disease (MRD)

## Indexed commentary on GIMEMA LAL2317 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=gimema-lal2317-nct03367299

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03367299", "email": "<work email>"}; the inbox owner confirms by the emailed link.